Clinical trial
BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable…
NCT00117637 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00117637 |
|---|---|
| Title | BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma |
| Official title | A Randomised, Open-label, Multi-centre Phase II Study of BAY43-9006 (Sorafenib) Versus Standard Treatment With Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma. |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | Sorafenib (Nexavar, BAY43-9006), Interferon |
| Enrollment | 189 |
| Start date | Jun 1, 2005 |
| Primary completion | Sep 1, 2006 |
| Completion | Mar 1, 2009 |
| First posted | Jul 8, 2005 |
| Last update posted | Oct 31, 2014 |
| Countries | France, Germany, Poland, Russia, Ukraine, United Kingdom, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: